The independent panel of experts heard testimony from Grail representatives, FDA officials and members of the public before deliberating on a recommendation that could pave the way for the $949 test to be covered by insurance, including Medicare, if approved.
Galleri claims to detect up to 50 cancer types, many of which lack routine screening programs, and is positioned as an add‑on to established tests such as colonoscopies and mammograms rather than a replacement.
The FDA has historically given weight to its advisory committees’ advice, though it retains final discretion. A positive recommendation would be a landmark for the burgeoning field of multi‑cancer blood diagnostics, where no test has yet cleared the agency’s safety and accuracy standards.
Grail’s submission is backed by two large clinical studies: a UK National Health Service trial involving more than 140,000 participants and a North American trial of over 35,000 individuals aged 50 and older. While the studies did not meet their primary endpoint of reducing overall mortality or lowering the combined incidence of stage III and IV cancers,
Experts acknowledged the mixed results. Cristian Tomasetti, director of early‑detection research at City of Hope, said the trials set “very ambitious” goals and that longer‑term data are needed to confirm whether regular testing can move diagnoses to earlier stages. Oncologist Tom Beer, chief medical officer for Abbott Cancer Diagnostics, echoed the sentiment, noting that many deadly cancers such as pancreatic cancer lack any screening tools.
The FDA’s review focuses on whether Galleri’s clinical data demonstrate reliable early detection and acceptable false‑positive and false‑negative rates. The agency may require marketing language to include warnings that a negative result does not rule out cancer and that a positive result is not a definitive diagnosis.
If the panel votes in favor of approval, Medicare’s recent decision to reimburse multi‑cancer detection tests that receive FDA clearance could make Galleri financially viable for a broader patient population, accelerating investment across the sector where hundreds of companies are racing to develop similar blood‑based assays.